Table 1.
Demographic and patient characteristics. Other in mode of transmission includes blood transfusions and vertical transmission. Other in region of origin and infection includes North and Central America, Asian and Oceania continents. p-values retrieved with chi-square test and Mann–Whitney U test.
| Patient Characteristics | Total | Late Presenters | Non-Late Presenters |
p-Value |
|---|---|---|---|---|
| Total, n (%) | 89,851 (100%) | 28,889 (50.4%) | 28,388 (49.6%) | |
| Sex, n (%) | 81,777 (91.0%) | 27,972 (50.6%) | 27,315 (49.4%) | <0.001 |
| Male | 60,852 (74.4%) | 20,955 (74.9%) | 20,969 (76.8%) | |
| Female | 20,925 (25.6%) | 7017 (25.1%) | 6346 (23.2%) | |
| Treatment status, n (%) | 19,605 (21.8%) | 10,905 (55.6%) | 8700 (44.4%) | <0.001 |
| Naïve | 11,487(58.6%) | 6040 (55.4%) | 5447 (62.6%) | |
| Treated | 8118 (41.4%) | 4865 (44.6%) | 3253 (37.4%) | |
| Median age at diagnosis in years IQR, n (%) | 25,530 (28.4%) | 11,929 (52.3%) | 10,897 (47.7%) | <0.001 |
| 33.0 (27.0–41.0) | 34.0 (28.0–43.0) | 31.0 (26.0–39.0) | ||
| ≤18 | 700 (2.7%) | 241 (2.0%) | 340 (3.1%) | <0.001 |
| 19–30 | 9767 (38.3%) | 4002 (33.5%) | 4823 (44.3%) | |
| 31–55 | 13,815 (54.1%) | 6920 (58.0%) | 5384 (49.4%) | |
| ≥56 | 1248 (4.9%) | 766 (6.4%) | 350 (3.2%) | |
| Mode of transmission, n (%) | 47,007 (52.3%) | 21,283 (49.5%) | 21,677 (50.5%) | <0.001 |
| Heterosexual | 15,165 (32.3%) | 7894 (37.1%) | 6071 (28.0%) | |
| MSM | 19,696 (41.9%) | 7657 (36.0%) | 10,693 (49.3%) | |
| IDU | 9532 (20.3%) | 4453 (20.9%) | 3896 (18.0%) | |
| Other | 2614 (5.6%) | 1279 (6.0%) | 1017 (4.7%) | |
| Region of origin, n (%) | 54,529 (60.7%) | 21,584 (50.1%) | 21,495 (49.9%) | <0.001 |
| Western Europe | 42,790 (78.5%) | 16,693 (77.4%) | 17,398 (81.0%) | |
| Eastern Europe | 1862 (3.4%) | 693 (3.2%) | 672 (3.1%) | |
| Africa | 5349 (9.8%) | 2250 (10.4%) | 1422 (6.6%) | |
| South America | 3233 (5.9%) | 1341 (6.2%) | 1460 (6.8%) | |
| Other | 1286 (2.4%) | 607 (2.8%) | 543 (2.5%) | |
| Subtype, n (%) | 54,176 (60.3%) | 17,449 (52.7%) | 15,638 (47.3%) | <0.001 |
| HIV-1 Subtype B | 35,454 (64.4%) | 11,966 (68.6%) | 11,745 (75.1%) | |
| HIV-1 Subtype non-B | 18,722 (34.6%) | 5483 (31.4%) | 3893 (24.9%) | |
| Distribution of non-B Subtypes | ||||
| HIV-1 CRF 01_AE | 447 (2.4%) | 183 (3.3%) | 108 (2.8%) | |
| HIV-1 CRF 02_AG | 2973 (15.9%) | 871 (15.9%) | 556 (14.3%) | |
| HIV-1 CRF 06_cpx | 248 (1.3%) | 81 (1.5%) | 58 (1.5%) | |
| HIV-1 CRF 14_BG | 1106 (5.9%) | 337 (6.1%) | 203 (5.2%) | |
| HIV-1 Subtype A | 2521 (13.5%) | 626 (11.4%) | 527 (13.5%) | |
| HIV-1 Subtype C | 1943 (10.4%) | 550 (10.0%) | 400 (10.3%) | |
| HIV-1 Subtype D | 307 (1.6%) | 102 (1.9%) | 74 (1.9%) | |
| HIV-1 Subtype F | 1619 (8.6%) | 444 (8.1%) | 362 (9.3%) | |
| HIV-1 Subtype G | 3815 (20.4%) | 1156 (21.1%) | 701 (28.0%) | |
| Others | 3743 (20.0%) | 1133 (20.7%) | 3893 (23.2%) | |
| Migrant status, n (%) | 54,520 (60.7%) | 21,584 (50.1%) | 21,495 (49.9%) | <0.001 |
| Migrant | 13,408 (24.6%) | 5588 (25.9%) | 4895 (22.8%) | |
| Native | 41,112 (75.4%) | 15,996 (74.1%) | 16,600 (77.2%) | |
| Recentness of infection, n (%) | 50,132 (55.8%) | 15,897 (52.6%) | 14,304 (47.4%) | <0.001 |
| Chronic | 29,972 (59.8%) | 11,069 (69.6%) | 7803 (54.6%) | |
| Recent | 20,160 (40.2%) | 4828 (30.4%) | 6501 (45.4%) | |
| Median CD4 count at diagnosis (cells/mL) IQR, n (%) | 57,277 (63.7%) | 28,889 (50.4%) | 28,388 (49.6%) | <0.001 |
| 348.0 (170.0–548.0) | 172.0 (69.0–264.0) | 550.0 (442.0–720.0) | ||
| Viral Load at diagnosis (log10 copies/mL) IQR, n (%) | 34,046 (37.9%) | 15,106 (50.8%) | 14,605 (49.2%) | <0.001 |
| 4.4 (3.4–5.1) | 4.7 (3.8–5.3) | 4.1 (3.1–4.8) | ||
| ≤4.0 | 12,994 (38.2%) | 4485 (29.7%) | 6819 (46.7%) | <0.001 |
| 4.1–5.0 | 11,715 (34.4%) | 5034 (33.3%) | 5295 (36.3%) | |
| ≥5.1 | 9337 (27.4%) | 5587 (37.0%) | 2491 (17.1%) |